weekly_roundup
BioTechSign Daily Catalyst Roundup - November 16, 2026
Top BioTechSign catalyst names today: BHVN, INO, EYPT, ADCT, SMMT, MLTX. FDA, clinical trial, grade-change, dilution, and sentiment signals.
BiotechSign AnalysisNovember 16, 2026
Daily Biotech Catalyst Digest: November 16, 2026
BHVN leads the current BioTechSign screen at 84.9/100 with a grade of A. The daily view combines FDA timing, clinical activity, publications, dilution risk, short interest, institutional/fund flow, and market-sentiment convergence into one research queue.
Top Catalyst Scores
| Ticker | Company | Score | Grade | Strongest Inputs |
|---|---|---|---|---|
| BHVN | Biohaven Ltd. | 84.9 | A | publication signal 100%, clinical activity 100%, dilution risk 50% |
| INO | Inovio Pharmaceuticals, Inc. | 84.5 | A | publication signal 100%, dilution risk 89%, short interest 70% |
| EYPT | EyePoint, Inc. | 84.2 | A | clinical activity 100%, short interest 70%, dilution risk 43% |
| ADCT | ADC Therapeutics SA | 83.3 | A | publication signal 100%, clinical activity 100%, dilution risk 50% |
| SMMT | Summit Therapeutics Inc. | 82.7 | A | publication signal 100%, clinical activity 100%, short interest 90% |
| MLTX | MoonLake Immunotherapeutics | 82.2 | A | clinical activity 100%, short interest 70%, publication signal 35% |
Recent Grade-Change Queue
- XENE (Xenon Pharmaceuticals) currently grades D with a 40.5/100 catalyst score. Main inputs: publication signal 100%, clinical activity 46%, short interest 30%.
- NVS (Novartis AG) currently grades B with a 73.3/100 catalyst score. Main inputs: publication signal 100%, clinical activity 100%, dilution risk 12%.
- FULC (Fulcrum Therapeutics) currently grades F with a 16.2/100 catalyst score. Main inputs: publication signal 100%, short interest 50%, dilution risk 49%.
- INBX (Inhibrx Inc) currently grades D with a 42.0/100 catalyst score. Main inputs: publication signal 100%, short interest 90%, dilution risk 51%.
- VTVT (vTv Therapeutics Inc.) currently grades D with a 35.4/100 catalyst score. Main inputs: clinical activity 38%, dilution risk 31%, short interest 30%.
- TLSA (Tiziana Life Sciences Ltd.) currently grades D with a 48.2/100 catalyst score. Main inputs: dilution risk 59%, clinical activity 50%, publication signal 15%.
- PASG (Passage Bio) currently grades D with a 42.3/100 catalyst score. Main inputs: publication signal 65%, dilution risk 53%, short interest 10%.
- RNA (Atrium Therapeutics, Inc.) currently grades F with a 26.2/100 catalyst score. Main inputs: short interest 70%, dilution risk 41%, clinical activity 17%.
What To Watch
Names with high clinical-trial and publication inputs deserve a pipeline read-through. Names with elevated dilution or short-interest inputs deserve tighter risk review before any catalyst trade. The purpose of this feed is to surface candidates for research, not to make buy or sell recommendations.